Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri

take kaplanoglu, gülnur; TANER, Mehmet Zeki

doi:10.24074/tjrms.2023-97020

Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri

Mehmet Zeki TANER, (Gazi Üniversitesi Tıp Fakültesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, Ankara, Türkiye)

Gülnur TAKE (Gazi Üniversitesi Tıp Fakültesi, Histoloji ve Embriyoloji ABD, Ankara, Türkiye)

Türk üreme tıbbı ve cerrahisi dergisi (Online)

9 5

Yıl: 2023 Cilt: 7 Sayı: 1 Sayfa Aralığı: 21 - 34 Metin Dili: Türkçe DOI: 10.24074/tjrms.2023-97020 İndeks Tarihi: 03-06-2023

Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri

Öz:

Kanser tedavisinde kullanılan tıbbi ve cerrahi yöntemlerin üreme organlarına zararlı etkileri vardır. Bu etkilere bağlı; infertilite, fertilitede azalma, abortus, erken doğum eylemi ve erken doğum, düşük doğum ağırlığı, gebelik komplikasyonlarında artış izlenmektedir. Bu konuda üzerinde en çok durulan ve incelenen gonadal toksisitedir. Buna yönelik uyulmas ı gereken kurallar ve hasta dan ışmanlığı bilgileri rehberler halinde yayın- lanmaktadır. Uterus üzerine olan etkilerden radyoterapi ayr ıntılı olarak incelenmiştir. Ancak kemoterapötik ajanların etkileri , önleme yöntem- leri üzerinde durulmamıştır. Bu derleme makelede, antrasiklin grubu kemoterapötik Doxorubisinin ; bir çok organ ve dokuya özellikle iskelet, üriner, mide barsak, damar düz kasları düz kaslar ve özellikle kalp kasına olan toksik etkileri, etki mekanizmaları, toksik etki mekanizmaları ve önleme yöntemleri incelenecektir. Uterin toksisite ayrıntılı incelenecek ve önleme önerileri gözden geçirilecektir.

Anahtar Kelime:

Uterine effects of Chemotherapy and Preventive Methods

Öz:

The treatment modalities of cancer have detrimental effects on reproductive organs and function. The clinical Picture of these effects are; de- creased fertility rate, infertility, abortion, preterm labor and delivery, low birth weight and increased preganancy complications. Gonadal toxici- ties are the most investigated and ,regulation and counseiling rules has been settled. There are societies guidelines for prevention and management of this complications. The effects of radiotherapy on uterus are extensively studied. But, research on effects, prevention and treatment of chemotherapeutics are scanty. In this review; we aim to evaluate the effects of antacyclins chemothepeuticss, mainly doxorubici n, effects on uterus, which is higly toxic on several organs, skletal muscle and urinary system, gastrointestinal system, vascular smooth muscles, and especially on cardiac tissue. The therapeutic and toxic mechanims, and clinical results of their effects on uterus, will be reviewed. Uter in toxicity, preven- tive intervention and treatment will be evaluated in detail.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. (Erişim tarihi:12.03.2023) [Link]
2. Johnston WT, Erdmann F, Newton R, Steliarova-Foucher E, Schüz J, Roman E. childhood cancer: Estimating regional and global incidence. cancer Epi- demiol. 2021;71(Pt B):101662. [crossref] [PubMed]
3. Siegel RL, Miller KD, Fuchs HE, Jemal A. cancer statistics, 2022. cA can- cer J clin. 2022;72(1):7-33. [crossref]
4. Gallicchio L, Devasia TP, Tonorezos E, Mollica MA, Mariotto A. Estimation of the Number of Individuals Living With Metastaticcancer in the United States. J Natl cancer Inst. 2022;114(11):1476-83. [crossref] [PubMed] [PMc]
5. Patterson P, McDonald FE, Zebrack B, Medlow S. Emerging issues among adolescent and young adult cancer survivors. Seminoncol Nurs. 2015;31:53- 9. [crossref] [PubMed]
6. Barr RD. Adolescents, young adults, and cancer-the international challenge. cancer. 2011;117:2245-9. [crossref] [PubMed]
7. Anderson RA, Amant F, Braat D, D'Angelo A, et al. ESHRE guideline: female fertility preservation† The ESHRE Guideline Group on Female Fertility Preser- vation. Human Reproduction open. 2020:4;1-17. [crossref] [PubMed] [PMc]
8. Long-Term Follow-Up Guidelines for Survivors ofchildhood, Adolescent, and Young Adult cancers 2018 LTFU Resource Guide. [Link]
9. (Erişim Tarihi: 12.03.2023 ) [Link]
10. National cancer Institute. Late Effects of Treatment for childhood cancer (PDQ®)_Health Professional Version (online) [Erişim Tarihi: 02. şubat 2023]. [Link]
11. Meaghan J. Griffiths,Amy L. Winship†, and Karla J. Hutt. Do cancer therapies damage the uterus and compromise fertility? Hum Reprod Update. 2020 Feb 28;26(2):161-73. [crossref] [PubMed]
12. van de Loo LEXM, van den Berg MH, overbeek A, van Dijk M, Damen L, Lambalk cB, et al. DcoG LATER-VEVo Study Group. Uterine function, preg- nancy complications, and pregnancy outcomes among female childhood can- cer survivors. Fertil Steril. 2019;111(2):372-80. [crossref] [PubMed]
13. Fang Deng, Xiuan Gao, Limian Xu, Weijie Li, Zubing Mei, caijun Xie. ob- stetric and perinatal outcomes in female survivors of childhood or adolescent cancer: Protocol of a meta-analysis of population-based cohort studies. PLoS one. 2022;17(9):e0273561. [crossref] [PubMed] [PMc]
14. Gerstl B, Sullivan E, chong S, chia D, Wand H, Anazodo A. Reproductive out- comes after a childhood and adolescent young adult cancer diagnosis in fe- male cancer survivors: a systematic review and meta-analysis. J Adolesc Young Adul. 2018;7:627-42. [crossref] [PubMed]
15. AZgardau A, Ray JG, Baxter NN, Nagamuthu c, Park AL, Gupta S, Nathan Pc. obstetrical and Perinatal outcomes in Female Survivors of childhood and Adolescent cancer: A Population-Based cohort Study. J Natl cancer Inst. 2022;114(4):553-64. [crossref] [PubMed] [PMc]
16. van Dorp W, Haupt R, Anderson RA, Mulder RL, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Su HI, Winther JF, Hudson MM, Levine JM, Wal- lace WH. Reproductive Function andoutcomes in Female Survivors ofchild- hood, Adolescent, and Young Adult cancer: A Review. J clin oncol. 2018;36(21):2169-80. [crossref] [PubMed] [PMc]
17. cathrine Everhøj, Filippa Nyboe Norsker, catherine Rechnitzer, et al. Effects of early maternal cancer and fertility treatment on the risk of adverse birth outcomes. E clinicalMedicine. 2022(4):46:101369. [crossref] [PubMed] [PMc]
18. Farland LV, Stern JE, Hwang SS, Liu cL, cabral H, Knowlton R, Gershman ST, coddington cc 3rd, Missmer SA. Early-life cancer, infertility, and risk of adverse pregnancy outcomes: a registry linkage study in Massachusetts. cancer causes control. 2021;32(2):169-80. [crossref] [PubMed] [PMc]
19. Anne-Lotte LF van der Kooi, Kelsey YW, van den Heuvel-Eibrink MM, Laven JSE, Wallace WHB, Anderson RA, Perinatal complications in female survivors of cancer: a systematic review and meta-analysis. European Journal ofcan- cer. 2019;111:126e-37. [crossref] [PubMed]
20. Haggar FA, Pereira G, Preen D, Holman cD, Einarsdottir K. Adverse obstet- ric and perinatal outcomes following treatment of adolescent and young adult cancer: a population-based cohort study. PLoS one. 2014;9(12):e113292. [crossref] [PubMed] [PMc]
21. Kaidar-Person o, Yoeli-Ullman R, Pillar N, Paluch-Shimon S, Poortmans P, Lawrence YR. obstetric complications at time of delivery amongst breast can- cer survivors: A population-based cohort study. Breast. 2022;62:170-78. [crossref] [PubMed] [PMc]
22. D'Ambrosio V, Vena F, Di Mascio D, Faralli I, Musacchio L, Boccherini c, Brunelli R, Piccioni MG, Benedetti Panici P, Giancotti A. obstetrical outcomes in women with history of breast cancer: a systematic review and meta-analy- sis. Breast cancer Res Treat. 2019;178(3):485-92. [crossref] [PubMed]
23. Mu-oz E, Fernandez I, Martinez M, Tocino A, Portela S, Pellicer A, García-Ve- lasco JA, Garrido N. oocyte donation outcome after oncological treatment in cancer survivors. Fertil Steril. 2015;103(1):205-13. [crossref] [PubMed]
24. Luke B, Brown MB, Missmer SA, Spector LG, Leach RE, Williams M, Koch L, Smith YR, Stern JE, Ball GD, Schymura MJ. Assisted reproductive tech- nology use and outcomes among women with a history of cancer. Hum Re- prod. 2016;31(1):183-9. [crossref] [PubMed] [PMc]
25. Marklund A, Nasiell J, Berger AS, Fagerberg A, Rodriguez-Wallberg KA. Preg- nancy Achieved Using Donor Eggs in cancer Survivors with Treatment-In- duced ovarian Failure: obstetric and Perinatal outcome. J Womens Health (Larchmt). 2018;27(7):939-45. [crossref] [PubMed] [PMc]
26. Jeve YB, Potdar N, opoku A, Khare M. Donor oocyte conception and preg- nancy complications: a systematic review and meta-analysis. BJ oG. 2016;123(9):1471-80. [crossref] [PubMed]
27. Berntsen S, Larsen E c, la cour Freiesleben N, Pinborg A. Pregnancy out- comes following oocyte donation. Best Pract Res clin obstet Gynaecol. 2021;70:81-91. [crossref] [PubMed]
28. Rodriguez-Wallberg KA, Berger AS, Fagerberg A, olofsson JI, Scherman- Pukk c, Lindqvist PG, Nasiell J. Increased incidence of obstetric and perina- tal complications in pregnancies achieved using donor oocytes and single embryo transfer in young and healthy women. A prospective hospital-based matched cohort study. Gynecol Endocrinol. 2019;35(4):314-9. [crossref] [PubMed]
29. Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, et al. ; Pancar- eLIFE consortium. Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the Pan care- LIFE consortium and the International Late Effects of childhood cancer Guideline Harmonization Group. Lancet oncol. 2021;22(2):e45-e56.
30. Leontien c M Kremer, Renée L Mulder, Kevin c oeffinger, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of childhood cancer Guideline Harmonization Group. Pediatr Bloodcancer. 2013;60(4):543-9. [crossref] [PubMed] [PMc]
31. Santaballa A, Márquez-Vega c, Rodríguez-Lescure Á, Rovirosa Á, Vázquez L, Zeberio-Etxetxipia I, Andrés M, Bassas L, ceballos-Garcia E, Domingo J, Manau-Trullas D. Multidisciplinary consensus on the criteria for fertility preser- vation in cancer patients. clin Transl oncol. 2022;24(2):227-43. [crossref] [PubMed] [PMc]
32. Pratson cL, Larkins M c, Karimian BH, curtis cM, Lepera PA, Brodish BN and Ju AW. The Impact of Smoking, Alcohol Use, Recurrent Disease, and Age on the Development of Neck Fibrosis in Head and Neckcancer Patients Following Radiation Therapy. Front. oncol. 2021;11:707418. [crossref] [PubMed] [PMc]
33. Sia J, Szmyd R, Hau E, Gee HE. Molecular Mechanisms of Radiation-In- duced cancer cell Death: A Primer. Front cell Dev Biol. 2020;8:41. [cross- ref] [PubMed] [PMc]
34. Varela-López A, et al. An update on the mechanisms related to cell death and toxicity of doxorubicin and the protective role of nutrients. Food chem Toxi- col. 2019;134(Suppl. 1):110834. [crossref] [PubMed]
35. chen SH, chan N-L, Hsieh T. New mechanistic and functional insights into DNA topoisomerases. Annu Rev Biochem. 2013;82(1):139-70. [crossref] [PubMed]
36. Baxter-Holland M, Dass cR. Doxorubicin, mesenchymal stem cell toxicity and antitumour activity: implications for clinical use. J Pharm Pharmacol, 2018;70(3):320-27. [crossref] [PubMed]
37. Liu B, Li H, Qu H, Sun B. Nitric oxide synthase expressions in ADR-induced cardiomyopathy in rats. BMB Rep. 2006;39(6):759-65. [crossref] [PubMed]
38. Lobo V, Patil A, Phatak A, chandra N. Free radicals, antioxidants and func- tional foods: impact on human health. Pharmacogn Rev 2010;4(8):118. [crossref] [PubMed] [PMc]
39. Burridge PW, et al. Human induced pluripotent stem cell-derived cardiomy- ocytes recapitulate the predilection of breast cancer patients to doxorubicin- induced cardiotoxicity. Nat Med. 2016;22(5):547-56. [crossref] [PubMed] [PMc]
40. Marci R, Mallozzi M, Di Benedetto L, Schimberni M, Mossa S, Soave I, Palomba S, caserta D. Radiations and female fertility. Reprod Biol Endocrinol. 2018;16(1):112. [crossref] [PubMed] [PMc]
41. Tanno B, Novelli F, Leonardi S, Merla c, Babini G, Giardullo P, et al. MiRNA- Mediated Fibrosis in the out-of-Target Heart following Partial-Body Irradia- tion. cancers (Basel). 2022;14(14):3463. [crossref] [PubMed] [PMc]
42. Teh WT, Stern c, chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes. Biomed Res Int. 2014;2014:482968. [crossref] [PubMed] [PMc]
43. Dehghan T, Mozdarani H, Khoradmehr A, Kalantar SM. Effects of gamma ra- diation on fetal development in mice. Int J Reprod Biomed. 2016;14(4):247- 54. [crossref] [PubMed] [PMc]
44. Reulen Rc, Zeegers MP, Wallace WH, Frobisher c, Taylor AJ, Lancashire ER, et al. British childhood cancer Survivor Study. Pregnancy outcomes among adult survivors of childhood cancer in the British childhood cancer Survivor Study. cancer Epidemiol Biomarkers Prev. 2009;18(8):2239-47. [crossref] [PubMed] [PMc]
45. critchley Ho, Wallace WH, Shalet SM, Mamtora H, Higginson J, Anderson Dc. Abdominal irradiation in childhood; the potential for pregnancy. Br J ob- stet Gynaecol. 1992;99(5):392-4. [crossref] [PubMed]
46. Bath LE, critchley Ho, chambers SE, Anderson RA, Kelnar cJ, Wallace WH. ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br Jobstet Gynaecol. 1999;106(12):1265-72. [crossref] [PubMed]
47. Larsen Ec, Müller J, Schmiegelow K, Rechnitzer c, Andersen AN. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J clin Endocrinol Metab. 2003;88(11):5307-14. [crossref] [PubMed]
48. Mahajan N. Fertility preservation in female cancer patients: An overview. J Hum Reprod Sci. 2015;8(1):3-13. [crossref] [PubMed] [PMc] 49. Tang M, Webber K. Fertility and pregnancy in cancer survivors. obstet Med. 2018;11:110-5. [crossref] [PubMed] [PMc]
50. cohen LE. cancer treatment and the ovary: the effects of chemotherapy and radiation. Ann N Y Acad Sci. 2008;1135:123-5. [crossref] [PubMed]
51. Winther JF, Boice JD Jr, Svendsen AL, Frederiksen K, Stovall M, olsen JH. Spontaneous abortion in a Danish population-based cohort of childhood can- cer survivors. J clin oncol. 2008;26(26):4340-6. [crossref] [PubMed] [PMc]
52. Norwitz ER, Stern HM, Grier H, Lee-Parritz A. Placenta percreta and uterine rupture associated with prior whole body radiation therapy. obstet Gynecol. 2001;98(5 Pt 2):929-31. [crossref] [PubMed]
53. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat oncol Biol Phys. 2009;73(5):1304-12. [crossref] [PubMed] [PMc]
54. Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. oncologist. 2006;11(2):96-110. [crossref] [PubMed]
55. Bar-Joseph H, Ben-Aharon I, Rizel S, Stemmer SM, Tzabari M, Shalgi R. Doxorubicin-induced apoptosis in germinal vesicle (GV) oocytes. Reprod Tox- icol. 2010;30(4):566-72. [crossref] [PubMed]
56. Morgan S, Lopes F, Gourley c, Anderson RA, Spears N. cisplatin and dox- orubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS one. 2013;8(7):e70117. [crossref] [PubMed] [PMc]
57. Ben-Aharon I, Bar-Joseph H, Tzarfaty G, Kuchinsky L, Rizel S, Stemmer SM, Shalgi R. Doxorubicin-induced ovarian toxicity. Reprod Biol Endocrinol. 2010;8:20. [crossref] [PubMed] [PMc]
58. chatterjee R, Helal M, Mobberley M, Ryder T, Bajoria R. Impaired steroido- genesis and apoptosis of granulosa-luteal cells in primary culture induced by cis-platinum. Am J obstet Gynecol. 2014;210(3):252.e1-7. [crossref] [PubMed]
59. Zhang T, He WH, Feng LL, Huang HG. Effect of doxorubicin-induced ovarian toxicity on mouse ovarian granulosa cells. Regul Toxicol Pharmacol. 2017;86:1-10. [crossref]
60. Mock V, Atkinson A, Barsevick AM, Berger AM, cimprich B, Eisenberger MA, Hinds P, Kaldor P, otis-Green SA, Piper BF. cancer-related fatigue. clinical Practice Guidelines in oncology. J Natl compr canc Netw. 2007;5(10):1054- 78.
61. Hydock DS, Lien cY, Jensen BT, Schneider cM, Hayward R. characteriza- tion of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat. Anticancer Res. 2011;31(6):2023-8.
62. Murata T, Yamawaki H, Hori M, Sato K, ozaki H, Karaki H. chronic vascular toxicity of doxorubicin in an organ-cultured artery. Br J Pharmacol. 2001;132(7):1365-73. [crossref] [PubMed] [PMc]
63. Matsuura c, Brunini TM, carvalho Lc, Resende Ac, carvalho JJ, de castro JP, Mendes-Ribeiro Ac. Exercise training in doxorubicin-induced heart failure: effects on the L-arginine-No pathway and vascular reactivity. J Am Soc Hy- pertens. 2010;4(1):7-13. [crossref] [PubMed]
64. Nishi K, Gunasekaran VP, Arunachalam J, Ganeshan M. Doxorubicin-induced female reproductive toxicity: an assessment of ovarian follicular apoptosis, cyclicity and reproductive tissue histology in Wistar rats. Drugchem Toxicol. 2018;41(1):72-81. [crossref] [PubMed]
65. Hoffman RK, Kim BJ, Shah PD,carver J, Ky B, Ryeom S. Damage to cardiac vasculature may be associated with breast cancer treatment-induced car- diotoxicity. cardiooncology. 2021;7(1):15. [crossref] [PubMed] [PMc]
66. Hydock DS, Lien cY, Jensen BT, Schneider cM, Hayward R. characteriza- tion of the effect of in vivo doxorubicin treatment on skeletal muscle function in the rat. Anticancer Res. 2011;31(6):2023-8.
67. Mellar P. Davis1, Rajiv Panikkar. Sarcopenia associated with chemotherapy and targeted agents for cancer therapy. Ann Palliat Med 2019;8(1):86-101. [crossref] [PubMed]
68. Tarpey MD, Amorese AJ, Balestrieri NP, Fisher-Wellman KH, Spangenburg EE. Doxorubicin causes lesions in the electron transport system of skeletal muscle mitochondria that are associated with a loss of contractile function. J Biol chem. 2019;294(51):19709-22. [crossref] [PubMed] [PMc]
69. Iguchi N, Dönmez Mİ, carrasco A Jr, Wilcox DT, Pineda RH, Malykhina AP, cost NG. Doxorubicin induces detrusor smooth muscle impairments through myosin dysregulation, leading to a risk of lower urinary tract dysfunction. Am J Physiol Renal Physiol. 2019;317(1):F197-F206.[crossref] [PubMed] [PMc]
70. Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation- Induced Lung Injury: Assessment and Management. chest. 2019;156(1):150- 62. [crossref] [PubMed] [PMc]
71. Liu X, Shao c, Fu J. Promising Biomarkers of Radiation-Induced Lung Injury: A Review. Biomedicines. 2021;9(9):1181. [crossref] [PubMed] [PMc]
72. Geng c, cui c, Wang c, Lu S, Zhang M, chen D, Jiang P. Systematic Eval- uations of Doxorubicin-Induced Toxicity in Rats Based on Metabolomics. AcS omega. 2020;6(1):358-66. . [crossref] [PubMed] [PMc]
73. Rozen G, Rogers P, chander S, Anderson R, McNally o, Umstad M, et al. clinical summary guide: reproduction in women with previous abdominopelvic radiotherapy or total body irradiation. Hum Reprod open. 2020;2020(4): hoaa045. [crossref] [PubMed] [PMc]
74. Evans J, Hannan NJ, Hincks c, Rombauts LJ, Salamonsen LA. Defective soil for a fertile seed? Altered endometrial development is detrimental to preg- nancy success. PLoS one. 2012;7(12):e53098. [crossref] [PubMed] [PMc]
75. Murray MJ, Meyer WR, Zaino RJ, Lessey BA, Novotny DB, Ireland K, Zeng D, Fritz MA. A critical analysis of the accuracy, reproducibility, and clinical util- ity of histologic endometrial dating in fertile women. Fertil Steril. 2004; 81(5):1333-43. [crossref] [PubMed]
76. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Am J obstet Gynecol. 1975;122(2):262-3. [crossref] [PubMed]
77. Alfer J, Fattahi A, Bleisinger N, Krieg J, Behrens R, Dittrich R, et al. En- dometrial Dating Method Detects Individual Maturation Sequences During the Secretory Phase. In Vivo. 2020;34(4):1951-63. [crossref] [PubMed] [PMc]
78. Achache H, Revel A. Endometrial receptivity markers, the journey to suc- cessful embryo implantation. Hum Reprod Update. 2006;12(6):731-46. [crossref] [PubMed]
79. Díaz-Gimeno P, Horcajadas JA, Martínez-conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón c. A genomic diagnostic tool for human endometrial re- ceptivity based on the transcriptomic signature. Fertil Steril. 2011;95(1):50-60, 60.e1-15. [crossref] [PubMed]
80. Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, Pellicer A, Valbuena D, Simón c. Window of implantation transcriptomic stratification reveals differ- ent endometrial subsignatures associated with live birth and biochemical pregnancy. Fertil Steril. 2017;108(4):703-10.e3. [crossref] [PubMed]
81. Lee YX, Su PH, Do AQ, Tzeng cR, Hu YM, chen cH, et al. cervical Secre- tion Methylation Is Associated with the Pregnancy outcome of Frozen- Thawed Embryo Transfer. Int J Mol Sci. 2023;24(2):1726. [crossref] [PubMed] [PMc]
82. Bassil R, casper R, Samara N, Hsieh TB, Barzilay E, orvieto R, Haas J. Does the endometrial receptivity array really provide personalized embryo trans- fer? J Assist Reprod Genet. 2018;35(7):1301-5. [crossref] [PubMed] [PMc]
83. Beneventi F, Locatelli E, Giorgiani G, Zecca M, Mina T, Simonetta M, et al. Adolescent and adult uterine volume and uterine artery Doppler blood flow among subjects treated with bone marrow transplantation or chemotherapy in pediatric age: a case-control study. Fertil Steril. 2015;103(2):455-61. [crossref] [PubMed]
84. Isaacs JD Jr, Wells cS, Williams DB, odem RR, Gast MJ, Strickler Rc. En- dometrial thickness is a valid monitoring parameter in cycles of ovulation in- duction with menotropins alone. Fertil Steril. 1996;65(2):262-6. [crossref] [PubMed]
85. Weissman A, Gotlieb L, casper RF. The detrimental effect of increased en- dometrial thickness on implantation and pregnancy rates and outcome in an in vitro fertilization program. Fertil Steril. 1999;71(1):147-9. [crossref] [PubMed]
86. Kasius A, Smit JG, Torrance HL, Eijkemans MJ, Mol BW, opmeer Bc, Broek- mans FJ. Endometrial thickness and pregnancy rates after IVF: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(4):530-41.[cross- ref] [PubMed]
87. Mahajan N, Sharma S. The endometrium in assisted reproductive technology: How thin is thin? J Hum Reprod Sci. 2016;9(1):3-8. [crossref] [PubMed] [PMc]
88. Kupesic S. Vascularisation de l'utérus en 3D et implantation [Three-dimen- sional ultrasonographic uterine vascularization and embryo implantation]. J Gynecol obstet Biol Reprod (Paris). 2004;33(1 Pt 2):S18-20. French.[cross- ref] [PubMed]
89. Milgrom SA, Vargas HA, Sala E, Kelvin JF, Hricak H, Goodman KA. Acute ef- fects of pelvic irradiation on the adult uterus revealed by dynamic contrast-en- hanced MRI. Br J Radiol. 2013;86(1031):20130334.[crossref] [PubMed] [PMc]
90. Arrivé L, chang Yc, Hricak H, Brescia RJ, Auffermann W, Quivey JM. Radi- ation-induced uterine changes: MR imaging. Radiology. 1989;170(1 Pt 1):55- 8. [crossref] [PubMed]
91. Platt T, Ladd ME, Paech D. 7 Tesla and Beyond: Advanced Methods and clin- ical Applications in Magnetic Resonance Imaging. Invest Radiol. 2021;56(11):705-25. [crossref] [PubMed] [PMc]
92. Bangerter NK, Taylor MD, Tarbox GJ, Palmer AJ, Park DJ. Quantitative tech- niques for musculoskeletal MRI at 7 Tesla. Quant Imaging Med Surg. 2016;6(6):715-30. [crossref] [PubMed] [PMc]
93. Santos DS, Goldenberg RcS. Doxorubicin-induced cardiotoxicity: from mech- anisms to development of efficient therapy (chapter 1). cardiotoxicity: Intech open. 2018;3-24. [crossref]
94. Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139: 111708. [crossref] [PubMed]
95. Langer SW. Dexrazoxane for the treatment of chemotherapy-related side ef- fects. cancer Manag Res. 2014;6:357-63. [crossref] [PubMed] [PMc]
96. de Baat Ec, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and chil- dren with cancer receiving anthracyclines. cochrane Database Syst Rev. 2022;9(9):cD014638. [crossref] [PubMed]
97. Padegimas A, clasen S, Ky B. cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends cardiovasc Med. 2020;30(1):22-8. [crossref] [PubMed] [PMc]
98. octavia Y, Tocchetti cG, Gabrielson KL, Janssens S, crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to thera- peutic strategies. J Mol cell cardiol 2012;52(6):1213-25. [crossref] [PubMed]
99. Syahputra RA, Harahap U, Dalimunthe A, Nasution MP, Satria D. The Role of Flavonoids as a cardioprotective Strategy against Doxorubicin-Induced cardiotoxicity: A Review. Molecules. 2022;27(4):1320. [crossref] [PubMed] [PMc]
100. Dickinson JM, D'Lugos Ac, Mahmood TN, ormsby Jc, Salvo L, Dedmon WL, et al. Exercise Protects Skeletal Muscle during chronic Doxorubicin Admin- istration. Med Sci Sports Exerc. 2017;49(12):2394-403.[crossref] [PubMed]
101. chen J, Zhou R, Feng Y, cheng L. Molecular mechanisms of exercise con- tributing to tissue regeneration. Signal Transduct Target Ther. 2022;7(1):383. [crossref] [PubMed] [PMc]
102. Martins RA, Minari AL, chaves MD, dos Santos RW, Barbisan LF, Ribeiro DA. Exercise preconditioning modulates genotoxicity induced by doxorubicin in multiple organs of rats. cell Biochem Funct. 2012;30(4):293-6. [crossref] [PubMed]
103. Kim JK, Pedram A, Razandi M, Levin ER. Estrogen prevents cardiomyocyte apoptosis through inhibition of reactive oxygen species and differential regu- lation of p38 kinase isoforms. J Biol chem. 2006;281(10):6760-7. [crossref] [PubMed]
104. Jafari Khorchani M, Samare-Najaf M, Abbasi A, Vakili S, Zal F. Effects of quercetin, vitamin E, and estrogen on Metabolic-Related factors in uterus and serum of ovariectomized rat models. Gynecol Endocrinol. 2021;37(8):764-8. [crossref] [PubMed]
105. Samare-Najaf M, Zal F, Safari S, Koohpeyma F, Jamali N. Stereological and histopathological evaluation of doxorubicin-induced toxicity in female rats' ovary and uterus and palliative effects of quercetin and vitamin E. Hum Exp Toxicol. 2020;39(12):1710-24. [crossref] [PubMed]
106. Drehsan Khedre,Amany Abdelhameid osman, Asmaa M Moghazy Amina Abdel Rahman.Propolis Protective Effects Against Doxorubicin-Induced Multi- organ Toxicity via Suppression ofoxidative Stress, Inflammation, Apoptosis, and Histopathological Alterations in Female Albino Rats. Biointerface Re- search in Applied chemistry 2021;12(1):1762-77. [crossref]
107. Mohamed HK, Mobasher MA, Ebiya RA, Hassen MT, Hagag HM, El-Sayed R, et al. Anti-Inflammatory, Anti-Apoptotic, and Antioxidant Roles of Honey, Royal Jelly, and Propolis in Suppressing Nephrotoxicity Induced by Doxoru- bicin in Male Albino Rats. Antioxidants (Basel). 2022;11(5):1029. [crossref] [PubMed] [PMc]

APA	TANER M, take kaplanoglu g (2023). Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. , 21 - 34. 10.24074/tjrms.2023-97020
Chicago	TANER Mehmet Zeki,take kaplanoglu gülnur Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. (2023): 21 - 34. 10.24074/tjrms.2023-97020
MLA	TANER Mehmet Zeki,take kaplanoglu gülnur Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. , 2023, ss.21 - 34. 10.24074/tjrms.2023-97020
AMA	TANER M,take kaplanoglu g Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. . 2023; 21 - 34. 10.24074/tjrms.2023-97020
Vancouver	TANER M,take kaplanoglu g Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. . 2023; 21 - 34. 10.24074/tjrms.2023-97020
IEEE	TANER M,take kaplanoglu g "Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri." , ss.21 - 34, 2023. 10.24074/tjrms.2023-97020
ISNAD	TANER, Mehmet Zeki - take kaplanoglu, gülnur. "Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri". (2023), 21-34. https://doi.org/10.24074/tjrms.2023-97020

APA	TANER M, take kaplanoglu g (2023). Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. Türk üreme tıbbı ve cerrahisi dergisi (Online), 7(1), 21 - 34. 10.24074/tjrms.2023-97020
Chicago	TANER Mehmet Zeki,take kaplanoglu gülnur Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. Türk üreme tıbbı ve cerrahisi dergisi (Online) 7, no.1 (2023): 21 - 34. 10.24074/tjrms.2023-97020
MLA	TANER Mehmet Zeki,take kaplanoglu gülnur Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. Türk üreme tıbbı ve cerrahisi dergisi (Online), vol.7, no.1, 2023, ss.21 - 34. 10.24074/tjrms.2023-97020
AMA	TANER M,take kaplanoglu g Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. Türk üreme tıbbı ve cerrahisi dergisi (Online). 2023; 7(1): 21 - 34. 10.24074/tjrms.2023-97020
Vancouver	TANER M,take kaplanoglu g Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri. Türk üreme tıbbı ve cerrahisi dergisi (Online). 2023; 7(1): 21 - 34. 10.24074/tjrms.2023-97020
IEEE	TANER M,take kaplanoglu g "Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri." Türk üreme tıbbı ve cerrahisi dergisi (Online), 7, ss.21 - 34, 2023. 10.24074/tjrms.2023-97020
ISNAD	TANER, Mehmet Zeki - take kaplanoglu, gülnur. "Kemoterapinin Uterusa Toksik Etkileri ve Korunma Yöntemleri". Türk üreme tıbbı ve cerrahisi dergisi (Online) 7/1 (2023), 21-34. https://doi.org/10.24074/tjrms.2023-97020